Clinical Trial Update: Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Actilyse (alteplase) 2 mg/2 mL versus saline for treating central venous catheter occlusion, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Venous Catheter Occlusion

Drugs mentioned

• Actilyse (alteplase)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Catheter Obstruction, Vascular Access Devices | Phase 3 | Status: COMPLETED | Results posted: 2015-05-01